ESPR Esperion Therapeutics, Inc.
Price Chart
Executive Summary
Esperion presented Phase 2 pediatric data and a CLEAR Outcomes post-hoc analysis at EAS 2026, showing bempedoic acid reduced LDL-C in children (range 6-25%) without new safety concerns, and that 42% of statin-intolerant adults achieved ≥30% LDL-C reduction. These data support ongoing Phase 3 pediatric studies and reinforce the product profile, but are interim scientific presentations without a hard regulatory catalyst or financial update.
Actionable Insight
These are supportive clinical data but not a near-term catalyst — the Phase 3 pediatric studies are still ongoing, and no regulatory filing was announced. The 42% ≥30% LDL-C reduction in CLEAR Outcomes is an incremental positive for the product's on-label messaging. Expect limited stock reaction unless subsequent regulatory news (FDA sNDA filing for pediatric indication) emerges. If you have a position, wait for concrete regulatory milestones.
Key Facts
- Phase 2 study in children aged 6-17 with HeFH showed weight-based bempedoic acid dosing produced adult-equivalent exposure and LDL-C reductions of 6-25% with no new safety signals.
- CLEAR Outcomes post-hoc analysis: 42% of statin-intolerant adults on bempedoic acid achieved ≥30% LDL-C reduction at 3 months, comparable to moderate-intensity statins.
- Factors associated with ≥30% LDL-C reduction included female sex, higher baseline LDL-C, and concurrent ezetimibe use.
- No new regulatory approvals, label expansions, financial results, or guidance were announced in this press release.
Financial Impact
No financial figures disclosed; data support potential label expansion to pediatric population and commercial differentiation.
Risk Factors
- Phase 3 pediatric study results could differ from Phase 2, delaying or preventing label expansion.
- Competition from newer non-statin LDL-C therapies (e.g., PCSK9 inhibitors, oral siRNA) could pressure commercial adoption.
- Esperion remains dependent on single-drug revenue; a pipeline setback would be disproportionately impactful.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300994 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
8-K
| $3.14 awaiting T+1 | awaiting T+1 | — | $3.15 (+0.32%) |
|
Jun 8, 2026
1d ago
|
DEFM14A
| $3.13 awaiting T+1 | awaiting T+1 | — | $3.15 (+0.64%) |
|
Jun 1, 2026
8d ago
|
8-K
| $3.14 $3.14 | · 0.00% | ▲ +0.72% | $3.15 (+0.32%) |
|
May 29, 2026
11d ago
|
PREM14A
| $3.13 $3.14 | ▲ +0.32% | ▲ +0.17% | $3.15 (+0.64%) |
|
May 26, 2026
14d ago
|
Press Release
| $3.12 $3.13 | ▲ +0.32% | ▲ +0.31% | $3.15 (+0.96%) |
|
May 1, 2026
5w ago
|
DEFA14A
| $3.12 $3.12 | · 0.00% | ▼ −0.80% | $3.15 (+0.96%) |
|
May 1, 2026
5w ago
|
Press Release
| $3.11 $3.12 | ▲ +0.32% | ▲ +0.66% | $3.15 (+1.29%) |
|
Apr 23, 2026
6w ago
|
Press Release
| $1.91 $1.91 | · 0.00% | ▼ −0.78% | $3.15 (+64.92%) |
|
Mar 17, 2026
12w ago
|
Insider Cluster
| $2.71 $2.51 | ▼ −7.38% | ▼ −5.98% | $3.15 (+16.24%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $2.70 $2.59 | ▼ −4.07% | ▼ −3.97% | $3.15 (+16.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access